Investors

Dear Prospective Investor,

I am excited to introduce you to Aprimus Diagnostics Inc., a pioneer in medical device technology. We are transforming traditional point-of-care (PoC) diagnostics with a new disposable tricoder reflectometer device and proprietary quantitative lateral flow assay (qLFA) test designed for diagnosing critical disease biomarkers. As the Co-Founder and Chief Executive Officer, I am proud to share our journey, achievements, and vision for the future.

 
At Aprimus, we aim to revolutionize healthcare through cutting-edge diagnostic solutions that enhance patient care and greatly improve clinical outcomes. Our dedicated team combines scientific rigor with technological advancements to develop and deliver high-quality diagnostic devices and tests that meet the evolving needs of the medical community. 

Over the past 5 years, we have made significant strides to design, calibrate, and manufacture our first flagship product, the D-dimer test. The test will identify and quantify the coagulation status of patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) within minutes and at a significant savings compared to similar laboratory tests. Our New and Unique Meter has been issued U.S. Patent No 12,055,479 on August 6th 2024, with other patents pending. Our plan is to begin clinical trials in 2025.

As we look to the future, we are committed to expanding our capabilities and exploring new frontiers in diagnostics. We are investing in research and development to create additional tests that offer faster turnaround times, greater precision, and increased accessibility and convenience. Additionally, we are exploring strategic partnerships and collaborations to leverage the latest advancements in biotechnology and artificial intelligence.

To realize our ambitious goals, we are seeking strategic investment partners who share our vision and are passionate about transforming healthcare. Your investment will enable us to accelerate our research and development efforts, expand our operational capacity, and bring our innovative diagnostic solutions to a broader market.

Investing in Aprimus Diagnostics presents a unique opportunity to be part of a dynamic and rapidly growing industry with significant potential for impact and returns. We are confident that our unique innovative approach, combined with our commitment to excellence and patient-centric focus, positions us for sustained success and growth.

I would be delighted to discuss our vision, strategy, and opportunities for collaboration in more detail. Please feel free to contact my team using the below form and they will reach out directly to schedule a meeting at your convenience.

Thank you for considering this exciting opportunity. Together, we can make a profound difference in the lives of patients and the future of healthcare.

Warm regards,

Jack Aronowitz
Chief Executive Officer
Aprimus Diagnostics Inc.
Delray Beach, FL

USA